ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1910

Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting

Julia Ford1, Xinyi Liu2, Allison Marshall1, Alessandra Zaccardelli1, Maria Prado1, Charlene Wiyarand3, Bing Lu4, Elizabeth Karlson2, Peter Schur1, Kevin D. Deane5 and Jeffrey A. Sparks2, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 5Division of Rheumatology, University of Colorado Denver, Aurora, CO

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, prevention and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Session Title: 4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Autoantibodies to cyclic citrullinated peptide (CCP) are present years prior to the onset of clinical RA. This observation was based on blood bank samples from individuals who later developed RA as well as prospective research studies in European arthralgia clinics. To expand the understanding of the association and timing of future RA in CCP+ individuals, we investigated the risk of progression to RA in a US hospital-based cohort of patients who were CCP+ without RA at presentation.

 

Methods: We performed a retrospective cohort study of CCP+ individuals seen at a US tertiary care system between 2003-2016 who were without classifiable rheumatic disease including RA per 2010 ACR/EULAR criteria by medical record review within one month of initial positive CCP. Incident RA by ACR/EULAR criteria and date of diagnosis were identified and confirmed independently by two rheumatologists through medical record review. We investigated the risk of progression to RA overall and stratified by CCP level (low: >1 to 2 times upper limit of normal [x ULN]; medium: >2 to 3x ULN; high: >3x ULN). We used multivariable Cox regression to evaluate the effect of CCP level on RA risk.

Results: We identified 340 CCP+ patients who at baseline were without RA or other rheumatic disease; 66% of the patients were female, and mean age was 55.0 years (SD 15.3). The most common indication for checking initial CCP was arthralgia (74%) followed by lung disease (10%). There were 73 (22%) patients who developed incident RA during 1047 person-years of follow-up. Absolute risk of progression to RA increased with higher CCP level (Figure), with 50% of patients progressing to RA by 5 years of follow-up. Compared to low CCP, medium (HR 2.73, 95% CI 1.21, 6.16) and high (HR 6.21, 95% CI 3.42, 11.3) CCP levels were strongly associated with progression to RA (Table). Women had increased risk of progression to RA (HR 1.75, 95% CI 1.01, 3.01) independent of CCP level, age, smoking, and BMI. Checking initial CCP for arthralgia was strongly predictive of progression to RA (HR 6.08, 95% CI 1.91, 19.3) compared to other indications.

 

Conclusion: In this study of CCP+ patients without RA identified through a US tertiary care system, RA risk increased substantially with increasing CCP level. This study provides support for close monitoring for development of RA among patients with CCP+ as well as the need for identifying strategies to mitigate this risk.

 

 


Disclosure: J. Ford, None; X. Liu, None; A. Marshall, None; A. Zaccardelli, None; M. Prado, None; C. Wiyarand, None; B. Lu, None; E. Karlson, None; P. Schur, None; K. D. Deane, Janssen, 2; J. A. Sparks, None.

To cite this abstract in AMA style:

Ford J, Liu X, Marshall A, Zaccardelli A, Prado M, Wiyarand C, Lu B, Karlson E, Schur P, Deane KD, Sparks JA. Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/impact-of-cyclic-citrullinated-peptide-autoantibody-level-on-progression-to-rheumatoid-arthritis-among-ccp-positive-patients-without-ra-in-a-clinical-setting/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-cyclic-citrullinated-peptide-autoantibody-level-on-progression-to-rheumatoid-arthritis-among-ccp-positive-patients-without-ra-in-a-clinical-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences